Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Frequency Therapeutics, Inc. - Common Stock (NQ: FREQ )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Nov 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Frequency Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ
From Kahn Swick & Foti, LLC
Via Business Wire
Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ
From Kahn Swick & Foti, LLC
Via Business Wire
FREQ Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Frequency Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Korro Bio and Frequency Therapeutics Announce Merger Agreement
From Korro Bio, Inc.
Via Business Wire
Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Why Did Bullfrog AI Stock Jump More Than 50%?
Trading volume and share price for BFRG took significant leaps forward on news the digital biopharmaceutical company will partner with Johns Hopkins University. 
Via MarketBeat
Topics Artificial Intelligence Initial Public Offering
Exposures Artificial Intelligence Securities Market
Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program
From Frequency Therapeutics
Via Business Wire
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics to Participate in September Investor and Medical Conferences
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program
From Frequency Therapeutics, Inc.
Via Business Wire
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
From Frequency Therapeutics, Inc.
Via Business Wire
NASDAQ:FREQ Long Term Shareholder Notice: Investigation of Potential Wrongdoing at Frequency Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 09/29/2021 -- Certain directors of Frequency Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points
From Frequency Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.